Revolution Medicines reports Q3 net loss $73.3M; cash $655M; clinical trials progressing

Revolution Medicines, Inc.

2022-Q3 EPS reported -$2.47 revenue$20,050,000

Net loss of $73.3M for Q3 2022, up from $52.9M in Q3 2021; revenue $3.4M from Sanofi collaboration.
Cash, equivalents, and marketable securities $655M as of Sep 30, 2022, boosted by July 2022 equity offering of $264.5M gross.
Phase 1/1b trials ongoing for RMC-6236 (RAS MULTI) and RMC-6291 (KRAS G12C); first data expected in 2023.
RMC-9805 (KRAS G12D) first patient dosing expected mid-2023.
Full-year 2022 GAAP net loss guidance reiterated at $260M-$280M; cash runway through 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Revolution Medicines, Inc. reported financial results for quarter ended September 30, 2022.

Period: quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 7, 2022, Revolution Medicines, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2022.

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

Revolution Medicines, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-279068

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.